ImmuPharma Shares Rise After Lupuzor Trial Confirmed
February 06 2023 - 3:58AM
Dow Jones News
By Elena Vardon
Shares in ImmuPharma PLC rose 24% on Monday after the group and
its partner Avion Pharmaceuticals confirmed that a Phase 2/3
adaptive trial will be the best design for its Lupuzor lupus
treatment's next clinical study.
At 0823 GMT, shares were up 0.63 pence at 3.25 pence.
The pharmaceutical company said the study is expected to start
in the second half of 2023 after submission through the Food and
Drug Administration and Prescription Drug User Fee Act process.
It said the study is expected to be cheaper and the overall
timelines faster as the need to stop and start two independent
trials, regulatory checks, ethics approvals and site setups are
avoided.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
February 06, 2023 03:43 ET (08:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Immupharma (LSE:IMM)
Historical Stock Chart
From Nov 2024 to Dec 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Dec 2023 to Dec 2024
